A familiar sleep aid is being reconsidered for pain
Melatonin is best known as a supplement people keep at home for insomnia or disrupted sleep. New research from the University of Sydney suggests it may deserve attention for something else as well: chronic musculoskeletal pain.
In a study published in PAIN, researchers analyzed evidence from 23 randomized controlled trials involving 2,028 adults and found that melatonin reduced pain on average by about 9 points on a 0 to 100 scale. In the most rigorous trials, the reduction was closer to 10 points. According to the supplied source text, that effect size falls in a range similar to commonly used pain medications such as opioids, nonsteroidal anti-inflammatory drugs, and paracetamol.
The finding does not mean melatonin has suddenly become a direct replacement for standard pain treatment. But it does suggest that a supplement already widely available, relatively inexpensive, and familiar to patients could have a practical role in reducing pain burden, especially where sleep problems and chronic pain overlap.
What the study examined
The analysis drew on trials conducted in multiple countries, including the United States, Russia, Brazil, Egypt, and China. Participants included people living with conditions such as low back pain, osteoarthritis, and fibromyalgia, as well as patients recovering from surgeries including joint replacements and spinal procedures.
That broad mix matters. Chronic musculoskeletal pain is not one disease, and recovery-related pain is not identical to long-term pain syndromes. By combining evidence across different settings, the researchers were looking for an overall signal: whether melatonin shows a repeatable pain-relieving effect across varied pain populations.
The answer, based on the supplied summary, was yes. The trials indicated that melatonin was associated with lower pain scores and better sleep quality. The latter point is especially important because pain and sleep frequently reinforce one another. Poor sleep can intensify the perception of pain, while pain can make restorative sleep harder to achieve.
That feedback loop is one reason the result stands out. A treatment that appears to improve both symptoms at once could be useful even if its effect on pain alone is moderate.
Why researchers see potential here
The study’s authors frame melatonin as part of a broader drug-repurposing opportunity. Instead of developing a brand-new medicine from scratch, repurposing asks whether a treatment already in use for one purpose can be deployed safely and effectively for another. That approach can shorten timelines and lower barriers to adoption, particularly when the safety profile of the treatment is already well understood.
In this case, the appeal is obvious. Melatonin is already common in households, relatively cheap, and familiar to clinicians and patients. Chronic musculoskeletal pain, meanwhile, is widespread, with the source text stating it affects up to 47% of people globally. Any intervention that might safely reduce dependence on higher-risk medications is likely to attract attention.
That risk-benefit context matters. Many standard pain drugs can be effective, but they also come with tradeoffs. Opioids carry well-known dependence and overdose risks. NSAIDs can cause gastrointestinal, renal, and cardiovascular problems in some patients, especially with prolonged use. Even medications viewed as routine can become problematic when chronic pain management stretches over months or years.
The possibility that melatonin could serve as an adjunct, rather than a substitute, is therefore one of the most relevant implications of the findings. If some patients can modestly lower their reliance on more hazardous drugs while also sleeping better, that could change how clinicians think about treatment combinations.
What the results do and do not say
The study summary supports several concrete conclusions. First, melatonin was associated with a measurable reduction in chronic musculoskeletal pain across the combined trial data. Second, it improved sleep quality. Third, the reported magnitude of pain reduction was in a range comparable to some widely used pain medications.
At the same time, the source text does not claim melatonin is a cure, nor does it show that every patient group benefits equally. Meta-analyses can identify an overall pattern while still leaving open questions about dose, duration, the types of patients most likely to respond, and how the supplement performs alongside other therapies in real-world care.
There is also a difference between statistical significance and clinical decision-making. A 9- to 10-point improvement on a 100-point pain scale may be meaningful for some patients and less so for others depending on baseline pain, function, and goals. That is one reason further research and clearer treatment protocols would matter before melatonin could move from promising evidence to standard pain-care guidance.
Still, the supplied study summary makes a credible case that the signal is strong enough to justify that next step. The evidence base spans more than 2,000 adults and 23 randomized controlled trials, which is a substantial foundation for a repurposing argument.
Why this could matter in everyday care
Chronic pain is often managed through combinations of physical therapy, exercise, behavior-based approaches, and medication. In practice, though, medication choices still shape quality of life, side-effect burden, and long-term safety. A low-cost option that might ease pain while also helping sleep would fit naturally into that broader, multimodal model of care.
It could be especially relevant for patients whose pain is tightly bound to insomnia or fragmented sleep. Clinicians have long recognized that pain does not occur in isolation; it affects energy, mood, mobility, and recovery. The link between pain and sleep makes melatonin’s dual signal more compelling than a narrow pain score alone.
The study also reflects a wider shift in medicine: finding practical uses for existing therapies rather than waiting solely on entirely new drugs. That does not lower the scientific bar. It simply changes the path from evidence to impact.
For now, the main takeaway is measured but meaningful. Melatonin, a supplement usually associated with bedtime routines, may have a broader clinical future in chronic pain management. If further work confirms these findings and identifies where the benefit is strongest, one of the simplest items in many medicine cabinets could take on a more serious role in everyday care.
This article is based on reporting by Medical Xpress. Read the original article.
Originally published on medicalxpress.com
